Wilder,
Thanks very much, that's exactly what I was looking for, and I, too, would welcome additional comment. Hopefully MZ will notice the cheap shares and make ALXN a research priority now that he's back from vacation. I feel he's SI's best handicapper of clinical trials (no pressure, MZ!). I agree that the review article was weird: some of the revenue numbers just plain did not make sense. I posted it mainly for the reference of trial progress.
I suspect Mr. Market will take a breather prior to the weekend, and I may attempt to fade high flyers, then on Tuesday pick up whatever seems near support that I like.
Along with ALXN, that would be SCIO, KOSP, CEGE, MLNM, CELG, and AFFX. Just bought ABGX yesterday, and wrote calls on it today; gunning for 15% (less transaction costs) by September expiration. If I can just do that regularly, I'll be OK again.
Hope you're hanging in there, too.
Cheers, Tuck |
